Composition for the Treatment of Coronavirus Infections
Simple SummaryContent extracted from patent full text and abstract with AI.
This patent describes a pharmaceutical or homeopathic composition for treating and preventing coronavirus infections. The invention uses extracts from the plant Artemisia annua, in combination with other plant extracts and active or supplementary ingredients, to enhance immune system strength and combat coronaviruses.
Use CasesContent extracted from patent full text and abstract with AI.
- Treatment of patients infected with coronaviruses, including COVID-19
- Prevention of coronavirus infections in at-risk populations
- Boosting immune system function for general health or during outbreaks
- Integration into dietary supplements for immune support
- Use alongside other therapies to enhance antiviral defense
BenefitsContent extracted from patent full text and abstract with AI.
- Utilizes natural plant-based extracts, potentially offering fewer side effects compared to synthetic drugs
- May provide both preventative and therapeutic effects against coronavirus infections
- Offers immune system support, which is valuable during pandemics or flu seasons
- Can be formulated as either a pharmaceutical or homeopathic remedy, allowing application in different regulatory contexts
- Potential for combination with other treatments for synergistic effects
Technical Classifications (CPCs)
Main Classifications
Health, Food & Consumer Tech
Sub Classifications
Medical & Vet Science
CPC Codes
Inventors & Applicants
Inventors
Applicants
Charite Univ Institut Fuer Mikrobiologie und Infektionsimmunologie
Freie Univ Berlin Institut Fuer Pharmazie
Hofmann & Sommer Gmbh und Co Kg Chemisch Pharmazeutische Fabrik
Patent Abstract
Die Erfindung betrifft pharmazeutische oder homöopathische Zubereitungen zur Behandlung von Infektionen mit Coronaviren, und auch zur Prävention von Infektionen und zur Stärkung des Immunsystems in welchen als Wirkstoffe Extrakte von Artemisia annua sowie weitere Pflanzenextrakte, weitere Wirkstoffe und ergänzenden Inhaltsstoffen enthalten sind.
Key Information
Publication No.
DE102020007979A1
Family ID
81972303
Publication Date
2022-06-30
Application No.
DE102020007979A
Application Date
2020-12-29
Priority Date
2020-12-29
Granted
No
Possible Cooperation
For further information please contact the transfer office.